Ariel Weinberger, PhD

Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari founded Autonomous in 2017 and has grown the company to a team of more than 20 scientists and robotics engineers in its own 20,000 square foot R&D facility in Rockville, MD.

Ari and the team have raised millions in funding from the U.S. Government and venture capital—and have developed new classes of RNA that enable precision and pan-variant medicines from COVID-19 to cancers.

Ari completed his Ph.D. in Biophysics at the University of California, Berkeley, where he was an NDSEG fellow and received the California HIV/AIDS Dissertation Prize. He completed his postdoctoral training as an NIH Ruth L. Kirschstein Fellow at Harvard Medical School.

Prior to founding Autonomous, Ari was a Principal Investigator and Wyss Institute Technology Development Fellow at Harvard Medical School.

Timothy Notton, PhD

Dr. Timothy Notton is Chief Scientific Officer at Autonomous and is the co-inventor of Autonomous’ Encrypted RNA™ platform and variant-proof therapeutic candidates from COVID-19 to RSV.

Tim earned his Ph.D. in Bioengineering from both the University of California, San Francisco and the University of California, Berkeley—where he developed an earlier platform technology to identify first-in-class antivirals to combat HIV and Zika.

At Autonomous, Tim leads the scientific team that has developed multiple RNA platform technologies and a suite of first-in-class therapeutic candidates—in addition to automated screening platforms and (inhalable) LNP delivery platforms. For his work, Tim was recently one of 50 early career scientists to be named a DARPA Riser at DARPA’s 60th Anniversary Conference.